市場調查報告書

胰臟癌治療藥的全球市場(2020年∼2026年)

Global Pancreatic Cancer Drugs Market 2020-2026

出版商 Orion Market Research Pvt Ltd 商品編碼 949447
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
胰臟癌治療藥的全球市場(2020年∼2026年) Global Pancreatic Cancer Drugs Market 2020-2026
出版日期: 2020年05月21日內容資訊: 英文
簡介

全球胰臟癌治療藥市場,預計在預測期間內的大幅度成長。胰臟癌的盛行率上升,及老年人口基礎,主要推動該市場的成長。部分免疫療法及標靶治療藥在胰臟癌的測試中,預期是今後市場成長的機會。

本報告提供全球胰臟癌治療藥市場的相關調查,市場趨勢和機會,成長及阻礙因素,各癌症的類型、治療類型、地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢
  • 開發平台分析
  • 法律規章

第3章 競爭情形

  • 企業佔有率分析
  • 主要策略分析
  • 主要企業分析
    • Eli Lilly and Co.
    • F. Hoffmann-La Roche AG
    • Novartis International AG
    • Boehringer Ingelheim GmbH
    • Merck & Co., Inc.

第4章 市場決策要素

  • 成長要素
  • 阻礙因素
  • 機會

第5章 市場區隔

  • 癌症的各類型
    • 外分泌
    • 內分泌
  • 各治療類型
    • 化療藥
    • 標靶治療藥
    • 免疫療法藥

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 其他
  • 其他地區

第7章 企業簡介

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co.
  • Cipla Ltd.
  • Clovis Oncology, Inc.
  • Eli Lilly and Co.
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Kura Oncology, Inc.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • PharmaCyte Biotech, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
目錄
Product Code: OMR2021766

Global Pancreatic Cancer Drugs Market Size, Share & Trends Analysis Report, By Cancer Type (Exocrine and Endocrine), By Treatment Type (Chemotherapy Drugs, Targeted Therapy Drugs, and Immunotherapy Drugs) and Forecast, 2020-2026

The global pancreatic cancer drugs market is estimated to grow significantly during the forecast period. Rising prevalence of pancreatic cancer and significant geriatric population base are primarily contributing to market growth. As per the United Nations, in 2019, 703 million people were aged 65 and over globally. By 2050, the number of older persons is anticipated to double to 1.5 billion. The percentage of the population aged 65 years and over increased from 6% in 1990 to 9% in 2019. Pancreatic adenocarcinoma primarily occurs after aged over 60 years. Therefore, the rising ageing population will eventually result in the increasing incidences of pancreatic adenocarcinoma. The management of pancreatic cancer in the geriatric population is gaining significance, which in turn, is contributing to the demand for chemotherapy, immunotherapy and targeted therapy in which drugs are used for the treatment of the condition. Some immunotherapy and targeted therapy drugs are under trials for the treatment of pancreatic cancer, which is offering an opportunity for the growth of the market.

Geographically, the global pancreatic cancer drugs market is segmented into four major regions, including North America, Europe, Asia-Pacific, and Rest of the World (RoW). In 2019, North America is anticipated to hold a significant share in the market owing to the significant rise in the incidences of pancreatic cancer and the potential availability of cancer treatment in the region. Asia-Pacific is estimated to witness considerable share in the market owing to the significant geriatric population base and rising incidences of pancreatic cancer in the region. As per the World Health Organization (WHO), in 2018, the number of new incidences of pancreas cancer was 116,291 in China, ranked 9th among all new cancer incidences in the country. This will contribute to the emerging demand for pancreatic cancer treatment in the country.

Some crucial players in the market include Eli Lilly and Co., F- Hoffman La-Roche AG, Novartis International AG, Boehringer Ingelheim GmbH, and Merck & Co., Inc. Mergers and acquisitions, product launches, and partnerships and collaborations are considered as crucial strategies adopted by the market players. For instance, in December 2019, AstraZeneca and Merck & Co., Inc. declared the US FDA approval of Lynparza (olaparib) for the maintenance treatment of patients with metastatic pancreatic adenocarcinoma. This is intended for those patients whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy treatment.

Research Methodology

The market study of the global pancreatic cancer drugs market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Pancreatic Cancer Drugs Market Research and Analysis by Cancer Type

2. Global Pancreatic Cancer Drugs Market Research and Analysis by Treatment Type

The Report Covers:

  • Comprehensive research methodology of the global pancreatic cancer drugs market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global pancreatic cancer drugs market.
  • Insights about market determinants, which are stimulating the global pancreatic cancer drugs market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography
    • 1.2.3. By Stakeholders

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Pipeline Analysis
  • 2.4. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Eli Lilly and Co.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. F. Hoffmann-La Roche AG
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Novartis International AG
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Boehringer Ingelheim GmbH
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Merck & Co., Inc.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Pancreatic Cancer Drugs Market by Cancer Type
    • 5.1.1. Exocrine
    • 5.1.2. Endocrine
  • 5.2. Global Pancreatic Cancer Drugs Market by Treatment Type
    • 5.2.1. Chemotherapy Drugs
    • 5.2.2. Targeted Therapy Drugs
    • 5.2.3. Immunotherapy Drugs

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AbbVie Inc.
  • 7.2. Amgen Inc.
  • 7.3. AstraZeneca plc
  • 7.4. Bayer AG
  • 7.5. Boehringer Ingelheim GmbH
  • 7.6. Bristol-Myers Squibb Co.
  • 7.7. Cipla Ltd.
  • 7.8. Clovis Oncology, Inc.
  • 7.9. Eli Lilly and Co.
  • 7.10. F. Hoffmann-La Roche AG
  • 7.11. GlaxoSmithKline plc
  • 7.12. Kura Oncology, Inc.
  • 7.13. Lupin Ltd.
  • 7.14. Merck & Co., Inc.
  • 7.15. Novartis International AG
  • 7.16. Pfizer Inc.
  • 7.17. PharmaCyte Biotech, Inc.
  • 7.18. Sun Pharmaceutical Industries Ltd.
  • 7.19. Teva Pharmaceutical Industries Ltd.

LIST OF TABLES

  • 1. GLOBAL PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL EXOCRINE PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL ENDOCRINE PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
  • 5. GLOBAL CHEMOTHERAPY DRUGS FOR PANCREATIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL TARGETED THERAPY DRUGS FOR PANCREATIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL IMMUNOTHERAPY DRUGS FOR PANCREATIC CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 8. GLOBAL PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 9. NORTH AMERICAN PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 10. NORTH AMERICAN PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)
  • 11. NORTH AMERICAN PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
  • 12. EUROPEAN PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. EUROPEAN PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)
  • 14. EUROPEAN PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
  • 15. ASIA-PACIFIC PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. ASIA-PACIFIC PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)
  • 17. ASIA-PACIFIC PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)
  • 18. REST OF THE WORLD PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY CANCER TYPE, 2019-2026 ($ MILLION)
  • 19. REST OF THE WORLD PANCREATIC CANCER DRUGS MARKET RESEARCH AND ANALYSIS BY TREATMENT TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL PANCREATIC CANCER DRUGS MARKET SHARE BY CANCER TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL PANCREATIC CANCER DRUGS MARKET SHARE BY TREATMENT TYPE, 2019 VS 2026 (%)
  • 3. GLOBAL PANCREATIC CANCER DRUGS MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD PANCREATIC CANCER DRUGS MARKET SIZE, 2019-2026 ($ MILLION)